Zkusit zdarma
Fate Therapeutics, Inc.

Fate Therapeutics, Inc.

FATE
Cena:
$ 2.25
+0.15 (7.14%)
Valuace
70
Růst
30
Zdraví
75
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue Estimates

Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue Estimates

10:40 13-05-2026

Fate Therapeutics (FATE) came out with a quarterly loss of $0.26 per share versus the Zacks Consensu...

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

8:30 13-05-2026

RECLAIM – LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refrac...

Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting

Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting

8:30 11-05-2026

Single dose treatment of FT819 without conditioning chemotherapy achieves lupus low disease activity...

Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819

Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819

8:30 05-05-2026

FDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program supp...

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

16:05 01-05-2026

SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage...

Fate Therapeutics Details Off-the-Shelf CAR T Progress in Lupus and Solid Tumors at Needham Conference

Fate Therapeutics Details Off-the-Shelf CAR T Progress in Lupus and Solid Tumors at Needham Conference

1:03 16-04-2026

Fate Therapeutics (NASDAQ: FATE) used a presentation at the Needham Healthcare Conference to outline...

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Recommendation of “Hold” from Brokerages

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Recommendation of “Hold” from Brokerages

2:56 23-03-2026

Fate Therapeutics, Inc. (NASDAQ: FATE - Get Free Report) has earned an average rating of "Hold" from...

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of “Hold” by Analysts

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of “Hold” by Analysts

2:44 01-02-2026

Shares of Fate Therapeutics, Inc. (NASDAQ: FATE - Get Free Report) have received a consensus recomme...

Cindy Tahl Sells 10,589 Shares of Fate Therapeutics (NASDAQ:FATE) Stock

Cindy Tahl Sells 10,589 Shares of Fate Therapeutics (NASDAQ:FATE) Stock

4:48 14-01-2026

Fate Therapeutics, Inc. (NASDAQ: FATE - Get Free Report) insider Cindy Tahl sold 10,589 shares of th...

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Recommendation of “Hold” from Brokerages

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Recommendation of “Hold” from Brokerages

2:00 07-01-2026

Shares of Fate Therapeutics, Inc. (NASDAQ: FATE - Get Free Report) have received a consensus recomme...

Fate Therapeutics (NASDAQ:FATE) Shares Pass Below Two Hundred Day Moving Average – What’s Next?

Fate Therapeutics (NASDAQ:FATE) Shares Pass Below Two Hundred Day Moving Average – What’s Next?

5:14 24-12-2025

Fate Therapeutics, Inc. (NASDAQ: FATE - Get Free Report) shares crossed below its 200-day moving ave...

Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference

Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference

8:00 25-11-2025

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate T...

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of “Hold” by Brokerages

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of “Hold” by Brokerages

2:00 18-11-2025

Shares of Fate Therapeutics, Inc. (NASDAQ: FATE - Get Free Report) have been assigned a consensus ra...

Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates

Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates

10:41 13-11-2025

Fate Therapeutics (FATE) came out with a quarterly loss of $0.27 per share versus the Zacks Consensu...

Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

8:30 13-11-2025

Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting ...

Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

11:01 04-11-2025

Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a like...

3 Cancer-Focused Stocks Showing Strong Pipeline Progress

3 Cancer-Focused Stocks Showing Strong Pipeline Progress

12:35 28-10-2025

Relay, Fate and Verastem advance promising cancer therapies, strengthening their pipelines in a rapi...

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of “Hold” by Analysts

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of “Hold” by Analysts

1:56 24-10-2025

Shares of Fate Therapeutics, Inc. (NASDAQ: FATE - Get Free Report) have earned a consensus rating of...

Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates

Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates

18:16 12-08-2025

Fate Therapeutics (FATE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensu...

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

16:01 12-08-2025

First patient treated with FT819 off-the-shelf CAR T-cell product candidate following fludarabine-fr...

close

IPSC-DERIVED NK CELLS CLINICAL TRIAL PIPELINE GAINS MOMENTUM: 12+ COMPANIES LEAD THE CHARGE IN PIONEERING NEW TREATMENTS | DELVEINSIGHT

16-02-2026
THE IPSC-DERIVED NK CELLS CLINICAL TRIAL ANALYSIS REPORT DELIVERS IMPORTANT INSIGHTS INTO ONGOING RE...
Více zde

FATE THERAPEUTICS REPORTS NEW EMPLOYEE INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)

03-02-2026
SAN DIEGO, FEB. 03, 2026 (GLOBE NEWSWIRE) -- FATE THERAPEUTICS, INC. (NASDAQ: FATE), A CLINICAL-STAG...
Více zde

FATE THERAPEUTICS REPORTS NEW EMPLOYEE INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)

05-01-2026
SAN DIEGO, JAN. 05, 2026 (GLOBE NEWSWIRE) -- FATE THERAPEUTICS, INC. (NASDAQ: FATE), A CLINICAL-STAG...
Více zde

FATE THERAPEUTICS TO PRESENT AT PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE

25-11-2025
SAN DIEGO, NOV. 25, 2025 (GLOBE NEWSWIRE) -- FATE THERAPEUTICS, INC. (THE “COMPANY” OR “FATE T...
Více zde

FATE THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATES

13-11-2025
AUTHORIZATION RECEIVED FROM UK AND EU AUTHORITIES TO ACTIVATE EX-US CLINICAL TRIAL SITES SUPPORTING ...
Více zde

FATE THERAPEUTICS REPORTS NEW EMPLOYEE INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)

04-11-2025
SAN DIEGO, NOV. 04, 2025 (GLOBE NEWSWIRE) -- FATE THERAPEUTICS, INC. (NASDAQ: FATE), A CLINICAL-STAG...
Více zde

FATE THERAPEUTICS PRESENTS NEW CLINICAL DATA AT ACR CONVERGENCE 2025 DEMONSTRATING IMMUNE REMODELING AND DURABLE RESPONSES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH FT819 OFF-THE-SHELF CAR T-CELL THERAPY

26-10-2025
AS OF A SEPTEMBER 25, 2025 DATA CUT-OFF-DATE, 10 PATIENTS WITH TREATMENT-REFRACTORY, MODERATE-TO-SEV...
Více zde

FATE THERAPEUTICS REPORTS NEW EMPLOYEE INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)

02-10-2025
SAN DIEGO, OCT. 02, 2025 (GLOBE NEWSWIRE) -- FATE THERAPEUTICS, INC. (NASDAQ: FATE), A CLINICAL-STAG...
Více zde

FATE THERAPEUTICS REPORTS NEW EMPLOYEE INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)

03-09-2025
SAN DIEGO, SEPT. 03, 2025 (GLOBE NEWSWIRE) -- FATE THERAPEUTICS, INC. (NASDAQ: FATE), A CLINICAL-STA...
Více zde

FATE THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATES

12-08-2025
FIRST PATIENT TREATED WITH FT819 OFF-THE-SHELF CAR T-CELL PRODUCT CANDIDATE FOLLOWING FLUDARABINE-FR...
Více zde

FATE THERAPEUTICS REPORTS NEW EMPLOYEE INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)

05-08-2025
SAN DIEGO, AUG. 05, 2025 (GLOBE NEWSWIRE) -- FATE THERAPEUTICS, INC. (NASDAQ: FATE), A CLINICAL-STAG...
Více zde

FATE THERAPEUTICS REPORTS NEW EMPLOYEE INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)

03-07-2025
SAN DIEGO, JULY 03, 2025 (GLOBE NEWSWIRE) -- FATE THERAPEUTICS, INC. (NASDAQ: FATE), A CLINICAL-STAG...
Více zde

FATE THERAPEUTICS ANNOUNCES UPDATED CLINICAL DATA FOR FT819 OFF-THE-SHELF CAR T-CELL PRODUCT CANDIDATE DEMONSTRATING DURABILITY OF DRUG-FREE REMISSION FOR SEVERE LUPUS NEPHRITIS AT EULAR 2025 CONGRESS

11-06-2025
ALL THREE PATIENTS TREATED WITH FT819 FOLLOWING FLUDARABINE-FREE CONDITIONING REGIMEN FOR SEVERE LUP...
Více zde

FATE THERAPEUTICS APPOINTS MATTHEW ABERNETHY, M.B.A., TO ITS BOARD OF DIRECTORS

30-05-2025
SAN DIEGO, MAY 30, 2025 (GLOBE NEWSWIRE) -- FATE THERAPEUTICS, INC. (NASDAQ: FATE), A CLINICAL-STAGE...
Více zde

FATE THERAPEUTICS ANNOUNCES PHASE 1 DATA PRESENTATION OF FT819 OFF-THE-SHELF CAR T-CELL PRODUCT CANDIDATE FOR SLE AT EULAR 2025 CONGRESS

28-05-2025
ORAL PRESENTATION OF CLINICAL DATA FROM FT819 PHASE 1 STUDY HIGHLIGHTS SAFETY AND EFFICACY OF FLUDAR...
Více zde

FATE THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATES

13-05-2025
ADDITIONAL PHASE 1 DATA FOR FT819 OFF-THE-SHELF CAR T-CELL PRODUCT CANDIDATE IN MODERATE-TO-SEVERE S...
Více zde

FATE THERAPEUTICS REPORTS NEW EMPLOYEE INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)

02-05-2025
SAN DIEGO, MAY 02, 2025 (GLOBE NEWSWIRE) -- FATE THERAPEUTICS, INC. (NASDAQ: FATE), A CLINICAL-STAGE...
Více zde

FATE THERAPEUTICS ANNOUNCES FIVE PRESENTATIONS ON OFF-THE-SHELF CAR T-CELL PRODUCT PLATFORM AT ASGCT ANNUAL MEETING

29-04-2025
UPDATED CLINICAL AND PRECLINICAL DATA SHOWCASE IPSC-DERIVED OFF-THE-SHELF CAR T-CELL THERAPY PRODUCT...
Více zde

FATE THERAPEUTICS RECEIVES REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION FROM FDA FOR FT819 TO TREAT MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

14-04-2025
–   RECOGNIZES POTENTIAL OF OFF-THE-SHELF CAR T-CELL THERAPY TO ADDRESS SIGNIFICANT UNMET NEED A...
Více zde

FATE THERAPEUTICS REPORTS NEW EMPLOYEE INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)

02-04-2025
SAN DIEGO, APRIL 02, 2025 (GLOBE NEWSWIRE) -- FATE THERAPEUTICS, INC. (NASDAQ: FATE), A CLINICAL-STA...
Více zde

FATE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND BUSINESS UPDATES

05-03-2025
PHASE 1 DOSE EXPANSION INITIATED FOR FT819 OFF-THE-SHELF CAR T-CELL PRODUCT CANDIDATE WITH FLUDARABI...
Více zde

FATE THERAPEUTICS REPORTS NEW EMPLOYEE INDUCEMENT AWARD UNDER NASDAQ LISTING RULE 5635(C)(4)

04-03-2025
SAN DIEGO, MARCH 04, 2025 (GLOBE NEWSWIRE) -- FATE THERAPEUTICS, INC. (NASDAQ: FATE), A CLINICAL-STA...
Více zde

FATE THERAPEUTICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES

14-02-2025
SAN DIEGO, FEB. 14, 2025 (GLOBE NEWSWIRE) -- FATE THERAPEUTICS, INC. (NASDAQ: FATE), A CLINICAL-STAG...
Více zde

FATE THERAPEUTICS REPORTS NEW EMPLOYEE INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)

04-02-2025
SAN DIEGO, FEB. 04, 2025 (GLOBE NEWSWIRE) -- FATE THERAPEUTICS, INC. (NASDAQ: FATE), A CLINICAL-STAG...
Více zde

FATE THERAPEUTICS REPORTS NEW EMPLOYEE INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)

03-01-2025
SAN DIEGO, JAN. 03, 2025 (GLOBE NEWSWIRE) -- FATE THERAPEUTICS, INC. (NASDAQ: FATE), A CLINICAL-STAG...
Více zde

FATE THERAPEUTICS PRESENTS NEW PHASE 1 CLINICAL DATA OF FT819 OFF-THE-SHELF, CAR T-CELL PRODUCT CANDIDATE FOR SYSTEMIC LUPUS ERYTHEMATOSUS

09-12-2024
ALL THREE PATIENTS TREATED IN FIRST DOSE COHORT ADMINISTERED FLUDARABINE-FREE CONDITIONING AND SHOW ...
Více zde

FATE THERAPEUTICS REPORTS NEW EMPLOYEE INDUCEMENT AWARD UNDER NASDAQ LISTING RULE 5635(C)(4)

03-12-2024
SAN DIEGO, DEC. 03, 2024 (GLOBE NEWSWIRE) -- FATE THERAPEUTICS, INC. (NASDAQ: FATE), A CLINICAL-STAG...
Více zde

FATE THERAPEUTICS ANNOUNCES LEADERSHIP TRANSITION

29-11-2024
BOB VALAMEHR, PH.D. MBA, TO BECOME PRESIDENT AND CEO JANUARY 1, 2025 SCOTT WOLCHKO TO RETIRE AS PRES...
Více zde

FATE THERAPEUTICS TO PRESENT AT UPCOMING DECEMBER INVESTOR CONFERENCES

26-11-2024
SAN DIEGO, NOV. 26, 2024 (GLOBE NEWSWIRE) -- FATE THERAPEUTICS, INC. (NASDAQ: FATE), A CLINICAL-STAG...
Více zde

FATE THERAPEUTICS PRESENTS 6-MONTH FOLLOW-UP DATA ON FIRST PATIENT TREATED IN PHASE 1 AUTOIMMUNITY STUDY WITH FLUDARABINE-FREE CONDITIONING AND FT819 OFF-THE-SHELF, 1XX CAR T-CELL PRODUCT CANDIDATE AT ACR CONVERGENCE

18-11-2024
27-YEAR-OLD AFRICAN AMERICAN-ASIAN WOMAN WITH ACTIVE LUPUS NEPHRITIS ACHIEVED DORIS CLINICAL REMISSI...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2025-11-13 00:00:008-KStáhnout
2025-11-13 00:00:0010-QStáhnout
2025-10-27 00:00:008-KStáhnout
2025-10-14 01:00:008-KStáhnout
2025-10-14 00:00:008-KStáhnout
2025-08-12 01:00:008-KStáhnout
2025-08-12 01:00:0010-QStáhnout
2025-08-12 00:00:008-KStáhnout
2025-08-12 00:00:0010-QStáhnout
2025-05-30 01:00:008-KStáhnout
2025-05-30 00:00:008-KStáhnout
2025-05-13 01:00:008-KStáhnout
2025-05-13 01:00:0010-QStáhnout
2025-05-13 00:00:008-KStáhnout
2025-05-13 00:00:0010-QStáhnout
2025-03-05 00:00:008-KStáhnout
2025-03-05 00:00:0010-KStáhnout
2025-03-04 23:00:008-KStáhnout
2025-03-04 23:00:0010-KStáhnout
2025-01-06 00:00:008-KStáhnout
2025-01-05 23:00:008-KStáhnout
2024-11-29 00:00:008-KStáhnout
2024-11-28 23:00:008-KStáhnout
2024-11-12 00:00:008-KStáhnout
2024-11-12 00:00:0010-QStáhnout
2024-11-11 23:00:008-KStáhnout
2024-11-11 23:00:0010-QStáhnout
2024-08-30 01:00:008-KStáhnout
2024-08-30 00:00:008-KStáhnout
2024-08-13 01:00:008-KStáhnout
2024-08-13 01:00:0010-QStáhnout
2024-08-13 00:00:008-KStáhnout
2024-08-13 00:00:0010-QStáhnout
2024-07-31 01:00:008-KStáhnout
2024-07-31 00:00:008-KStáhnout
2024-06-10 01:00:008-KStáhnout
2024-06-10 00:00:008-KStáhnout
2024-06-07 01:00:008-KStáhnout
2024-06-07 00:00:008-KStáhnout
2024-05-31 01:00:008-KStáhnout
2024-05-31 00:00:008-KStáhnout
2024-05-09 01:00:008-KStáhnout
2024-05-09 01:00:0010-QStáhnout
2024-05-09 00:00:008-KStáhnout
2024-05-09 00:00:0010-QStáhnout
2024-03-21 00:00:008-KStáhnout
2024-03-20 23:00:008-KStáhnout
2024-02-26 00:00:008-KStáhnout
2024-02-26 00:00:0010-KStáhnout
2024-02-25 23:00:008-KStáhnout
2024-02-25 23:00:0010-KStáhnout
2023-11-08 00:00:008-KStáhnout
2023-11-08 00:00:0010-QStáhnout
2023-11-07 23:00:008-KStáhnout
2023-11-07 23:00:0010-QStáhnout
2023-09-01 01:00:008-KStáhnout
2023-09-01 00:00:008-KStáhnout
2023-08-08 01:00:008-KStáhnout
2023-08-08 01:00:0010-QStáhnout
2023-08-08 00:00:008-KStáhnout
2023-08-08 00:00:0010-QStáhnout
2023-06-09 01:00:008-KStáhnout
2023-06-09 00:00:008-KStáhnout
2023-06-08 01:00:008-KStáhnout
2023-06-08 00:00:008-KStáhnout
2023-06-07 01:00:008-KStáhnout
2023-06-07 00:00:008-KStáhnout
2023-05-03 01:00:008-KStáhnout
2023-05-03 01:00:0010-QStáhnout
2023-05-03 00:00:008-KStáhnout
2023-05-03 00:00:0010-QStáhnout
2023-04-19 01:00:008-KStáhnout
2023-04-19 00:00:008-KStáhnout
2023-02-28 00:00:008-KStáhnout
2023-02-28 00:00:0010-KStáhnout
2023-02-27 23:00:008-KStáhnout
2023-02-27 23:00:0010-KStáhnout
2023-01-05 00:00:008-KStáhnout
2023-01-04 23:00:008-KStáhnout
2022-11-07 00:00:008-KStáhnout
2022-11-06 23:00:008-KStáhnout
2022-11-03 00:00:008-KStáhnout
2022-11-03 00:00:0010-QStáhnout
2022-11-02 23:00:008-KStáhnout
2022-11-02 23:00:0010-QStáhnout
2022-08-03 01:00:008-KStáhnout
2022-08-03 01:00:0010-QStáhnout
2022-08-03 00:00:008-KStáhnout
2022-08-03 00:00:0010-QStáhnout
2022-06-30 01:00:008-KStáhnout
2022-06-30 00:00:008-KStáhnout
2022-06-13 01:00:008-KStáhnout
2022-06-13 00:00:008-KStáhnout
2022-05-04 01:00:008-KStáhnout
2022-05-04 01:00:0010-QStáhnout
2022-05-04 00:00:008-KStáhnout
2022-05-04 00:00:0010-QStáhnout
2022-02-28 00:00:008-KStáhnout
2022-02-28 00:00:0010-KStáhnout
2022-02-27 23:00:008-KStáhnout
2022-02-27 23:00:0010-KStáhnout
2021-12-14 00:00:008-KStáhnout
2021-12-13 23:00:008-KStáhnout
2021-11-04 00:00:008-KStáhnout
2021-11-04 00:00:0010-QStáhnout
2021-11-03 23:00:008-KStáhnout
2021-11-03 23:00:0010-QStáhnout
2021-08-04 01:00:008-KStáhnout
2021-08-04 01:00:0010-QStáhnout
2021-08-04 00:00:008-KStáhnout
2021-08-04 00:00:0010-QStáhnout
2021-06-07 01:00:008-KStáhnout
2021-06-07 00:00:008-KStáhnout
2021-05-05 01:00:008-KStáhnout
2021-05-05 01:00:0010-QStáhnout
2021-05-05 00:00:008-KStáhnout
2021-05-05 00:00:0010-QStáhnout
2021-03-25 00:00:008-KStáhnout
2021-03-24 23:00:008-KStáhnout
2021-02-24 00:00:008-KStáhnout
2021-02-24 00:00:0010-KStáhnout
2021-02-23 23:00:008-KStáhnout
2021-02-23 23:00:0010-KStáhnout
2021-01-08 00:00:008-KStáhnout
2021-01-07 23:00:008-KStáhnout
2020-12-22 00:00:008-KStáhnout
2020-12-21 23:00:008-KStáhnout
2020-12-07 00:00:008-KStáhnout
2020-12-06 23:00:008-KStáhnout
2020-11-05 00:00:008-KStáhnout
2020-11-05 00:00:0010-QStáhnout
2020-11-04 23:00:008-KStáhnout
2020-11-04 23:00:0010-QStáhnout
2020-08-19 01:00:008-KStáhnout
2020-08-19 00:00:008-KStáhnout
2020-08-05 01:00:008-KStáhnout
2020-08-05 01:00:0010-QStáhnout
2020-08-05 00:00:008-KStáhnout
2020-08-05 00:00:0010-QStáhnout
2020-06-10 01:00:008-KStáhnout
2020-06-10 00:00:008-KStáhnout
2020-05-11 01:00:008-KStáhnout
2020-05-11 01:00:0010-QStáhnout
2020-05-11 00:00:008-KStáhnout
2020-05-11 00:00:0010-QStáhnout
2020-05-05 01:00:008-KStáhnout
2020-05-05 00:00:008-KStáhnout
2020-04-28 01:00:008-KStáhnout
2020-04-28 00:00:008-KStáhnout
2020-04-02 01:00:008-KStáhnout
2020-04-02 00:00:008-KStáhnout
2020-03-02 00:00:008-KStáhnout
2020-03-02 00:00:0010-KStáhnout
2020-03-01 23:00:008-KStáhnout
2020-03-01 23:00:0010-KStáhnout
2020-01-10 00:00:008-KStáhnout
2020-01-09 23:00:008-KStáhnout
2019-11-14 00:00:008-KStáhnout
2019-11-13 23:00:008-KStáhnout
2019-11-05 00:00:008-KStáhnout
2019-11-05 00:00:0010-QStáhnout
2019-11-04 23:00:008-KStáhnout
2019-11-04 23:00:0010-QStáhnout
2019-09-13 01:00:008-KStáhnout
2019-09-13 00:00:008-KStáhnout
2019-08-06 01:00:008-KStáhnout
2019-08-06 01:00:0010-QStáhnout
2019-08-06 00:00:008-KStáhnout
2019-08-06 00:00:0010-QStáhnout
2019-07-17 01:00:008-KStáhnout
2019-07-17 00:00:008-KStáhnout
2019-05-07 01:00:008-KStáhnout
2019-05-07 01:00:0010-QStáhnout
2019-05-07 00:00:008-KStáhnout
2019-05-07 00:00:0010-QStáhnout
2019-03-18 00:00:008-KStáhnout
2019-03-17 23:00:008-KStáhnout
2019-03-05 00:00:008-KStáhnout
2019-03-05 00:00:0010-KStáhnout
2019-03-04 23:00:008-KStáhnout
2019-03-04 23:00:0010-KStáhnout
2019-01-04 00:00:008-KStáhnout
2019-01-03 23:00:008-KStáhnout
2018-11-21 00:00:008-KStáhnout
2018-11-20 23:00:008-KStáhnout
2018-11-07 00:00:008-KStáhnout
2018-11-06 23:00:008-KStáhnout
2018-11-01 00:00:008-KStáhnout
2018-11-01 00:00:0010-QStáhnout
2018-10-31 23:00:008-KStáhnout
2018-10-31 23:00:0010-QStáhnout
2018-09-21 01:00:008-KStáhnout
2018-09-21 00:00:008-KStáhnout
2018-09-18 01:00:008-KStáhnout
2018-09-18 00:00:008-KStáhnout
2018-09-13 01:00:008-KStáhnout
2018-09-13 00:00:008-KStáhnout
2018-08-06 01:00:008-KStáhnout
2018-08-06 01:00:0010-QStáhnout
2018-08-06 00:00:008-KStáhnout
2018-08-06 00:00:0010-QStáhnout
2018-08-01 01:00:008-KStáhnout
2018-08-01 00:00:008-KStáhnout
2018-06-01 01:00:008-KStáhnout
2018-06-01 00:00:008-KStáhnout
2018-05-18 01:00:008-KStáhnout
2018-05-18 00:00:008-KStáhnout
2018-05-10 01:00:008-KStáhnout
2018-05-10 01:00:0010-QStáhnout
2018-05-10 00:00:008-KStáhnout
2018-05-10 00:00:0010-QStáhnout
2018-05-04 01:00:008-KStáhnout
2018-05-04 00:00:008-KStáhnout
2018-03-05 00:00:008-KStáhnout
2018-03-05 00:00:0010-KStáhnout
2018-03-04 23:00:008-KStáhnout
2018-03-04 23:00:0010-KStáhnout
2018-01-17 00:00:008-KStáhnout
2018-01-16 23:00:008-KStáhnout
2017-12-14 00:00:008-KStáhnout
2017-12-13 23:00:008-KStáhnout
2017-12-12 00:00:008-KStáhnout
2017-12-11 23:00:008-KStáhnout
2017-11-01 00:00:008-KStáhnout
2017-11-01 00:00:0010-QStáhnout
2017-10-31 23:00:008-KStáhnout
2017-10-31 23:00:0010-QStáhnout
2017-08-14 01:00:008-KStáhnout
2017-08-14 01:00:0010-QStáhnout
2017-08-14 00:00:008-KStáhnout
2017-08-14 00:00:0010-QStáhnout
2017-07-14 01:00:008-KStáhnout
2017-07-14 00:00:008-KStáhnout
2017-05-15 01:00:008-KStáhnout
2017-05-15 01:00:0010-QStáhnout
2017-05-15 00:00:008-KStáhnout
2017-05-15 00:00:0010-QStáhnout
2017-05-08 01:00:008-KStáhnout
2017-05-08 00:00:008-KStáhnout
2017-03-16 00:00:008-KStáhnout
2017-03-16 00:00:0010-KStáhnout
2017-03-15 23:00:008-KStáhnout
2017-03-15 23:00:0010-KStáhnout
2016-11-29 00:00:008-KStáhnout
2016-11-28 23:00:008-KStáhnout
2016-11-22 00:00:008-KStáhnout
2016-11-21 23:00:008-KStáhnout
2016-11-07 00:00:008-KStáhnout
2016-11-07 00:00:0010-QStáhnout
2016-11-06 23:00:008-KStáhnout
2016-11-06 23:00:0010-QStáhnout
2016-09-07 01:00:008-KStáhnout
2016-09-07 00:00:008-KStáhnout
2016-08-08 01:00:008-KStáhnout
2016-08-08 01:00:0010-QStáhnout
2016-08-08 00:00:008-KStáhnout
2016-08-08 00:00:0010-QStáhnout
2016-05-12 01:00:008-KStáhnout
2016-05-12 00:00:008-KStáhnout
2016-05-09 01:00:008-KStáhnout
2016-05-09 01:00:0010-QStáhnout
2016-05-09 00:00:008-KStáhnout
2016-05-09 00:00:0010-QStáhnout
2016-03-03 00:00:008-KStáhnout
2016-03-03 00:00:0010-KStáhnout
2016-03-02 23:00:008-KStáhnout
2016-03-02 23:00:0010-KStáhnout
2016-01-14 00:00:008-KStáhnout
2016-01-13 23:00:008-KStáhnout
2015-12-07 00:00:008-KStáhnout
2015-12-06 23:00:008-KStáhnout
2015-11-03 00:00:008-KStáhnout
2015-11-03 00:00:0010-QStáhnout
2015-11-02 23:00:008-KStáhnout
2015-11-02 23:00:0010-QStáhnout
2015-10-13 01:00:008-KStáhnout
2015-10-13 00:00:008-KStáhnout
2015-08-05 01:00:008-KStáhnout
2015-08-05 01:00:0010-QStáhnout
2015-08-05 00:00:008-KStáhnout
2015-08-05 00:00:0010-QStáhnout
2015-05-21 01:00:008-KStáhnout
2015-05-21 00:00:008-KStáhnout
2015-05-15 01:00:008-KStáhnout
2015-05-15 00:00:008-KStáhnout
2015-05-07 01:00:008-KStáhnout
2015-05-07 01:00:0010-QStáhnout
2015-05-07 00:00:008-KStáhnout
2015-05-07 00:00:0010-QStáhnout
2015-05-06 01:00:008-KStáhnout
2015-05-06 00:00:008-KStáhnout
2015-03-12 00:00:008-KStáhnout
2015-03-12 00:00:0010-KStáhnout
2015-03-11 23:00:008-KStáhnout
2015-03-11 23:00:0010-KStáhnout
2015-01-30 00:00:008-KStáhnout
2015-01-29 23:00:008-KStáhnout
2015-01-07 00:00:008-KStáhnout
2015-01-06 23:00:008-KStáhnout
2014-12-30 00:00:008-KStáhnout
2014-12-29 23:00:008-KStáhnout
2014-12-18 00:00:008-KStáhnout
2014-12-17 23:00:008-KStáhnout
2014-11-17 00:00:008-KStáhnout
2014-11-16 23:00:008-KStáhnout
2014-11-12 00:00:008-KStáhnout
2014-11-12 00:00:0010-QStáhnout
2014-11-11 23:00:008-KStáhnout
2014-11-11 23:00:0010-QStáhnout
2014-08-12 01:00:008-KStáhnout
2014-08-12 01:00:0010-QStáhnout
2014-08-12 00:00:008-KStáhnout
2014-08-12 00:00:0010-QStáhnout
2014-08-05 01:00:008-KStáhnout
2014-08-05 00:00:008-KStáhnout
2014-06-11 01:00:008-KStáhnout
2014-06-11 00:00:008-KStáhnout
2014-05-13 01:00:008-KStáhnout
2014-05-13 01:00:0010-QStáhnout
2014-05-13 00:00:008-KStáhnout
2014-05-13 00:00:0010-QStáhnout
2014-03-17 00:00:008-KStáhnout
2014-03-17 00:00:0010-KStáhnout
2014-03-16 23:00:008-KStáhnout
2014-03-16 23:00:0010-KStáhnout
2014-01-10 00:00:008-KStáhnout
2014-01-09 23:00:008-KStáhnout
2013-11-13 00:00:008-KStáhnout
2013-11-13 00:00:0010-QStáhnout
2013-11-12 23:00:008-KStáhnout
2013-11-12 23:00:0010-QStáhnout
preloader